drugset / Trial / NCT04202653
Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)
Phase 2
Completed
24 enrolled
Tongji Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a single-center, randomized, prospective, open-label Phase 2 Clinical trial to evaluate efficacy and safety of ETV and TQ-A3334 combinated with/without inhibitor of TQ-B2450 versus ETV alone in chronic hepatitis B patients. Patients were randomized to one of 3 different antiviral treatment.
Timeline
- Start
- 2020-01-01
- Primary completion
- 2023-06-30
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benmelstobart | Monoclonal antibody | — | Intravenous |
| Subject | Entecavir | Small molecule | 0.5 mg | Oral |
| Subject | TQ-A3334 | Other / unclassified | — | Oral |